NCT05026060 Measurement of Brain Perfusion by a MR Perfusion Imaging Called eASL in Children's Cerebral Arteriopathies.
| NCT ID | NCT05026060 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Cerebral Arteriopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-05-02 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-05-02 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MR sequence called MR-ASL is used to measure cerebral perfusion in children. This ASL sequence is used with a unique post-labeling delay (PLD) due to the technical impossibility of setting different post-labeling delays. The use of a single post-labeling, chosen by the pediatric radiology department of the Necker hospital, optimal in children without arteriopathy, may not be suitable for the lengthened arterial transit time of the spins marked in the pathological carotid network of a child with arterial disease. Recently, ASL sequences with multiple delays (multi-PLD, called eASL) have been developed to overcome this limitation in arterial disease. To date, their use in the pre- and post-treatment evaluation of a child with acute or chronic arterial disease has not been evaluated. The study hypothesis is that this eASL sequence is more efficient than single-delay ASL in measuring cerebral perfusion. The study will be performed in a population of children with acute or chronic arterial disease.
Eligibility Criteria
Inclusion Criteria: * Minor patients aged 0 to 18 with acute or chronic arterial disease: diagnosis of Moya-moya, diagnosis of sickle cell disease, acute and chronic arterial infarction. * Necessity of diagnostic MR with standard ASL sequences for the care. * Holders of parental authority and patients informed and not opposed to their participation in the study. Exclusion Criteria: * Usual contraindications to MR. * Movement during ASL / eASL sequences.
Contact & Investigator
Nathalie BODDAERT, MD, PhD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05026060 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Cerebral Arteriopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05026060 currently recruiting?
Yes, NCT05026060 is actively recruiting participants. Contact the research team at nathalie.boddaert@aphp.fr for enrollment information.
Where is the NCT05026060 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05026060 clinical trial?
NCT05026060 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Nathalie BODDAERT, MD, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 50 participants.